Which has stronger valuation & earnings, SRRK or AVBP?

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is SRRK or AVBP more profitable?

ArriVent BioPharma's return on equity of -52.47% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -159.92% -90.71% ArriVent BioPharma N/A -52.47% -48.68%

Does the media refer more to SRRK or AVBP?

In the previous week, Scholar Rock had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for Scholar Rock and 12 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.24 beat Scholar Rock's score of -0.01 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to GRFS or AVBP?

In the previous week, ArriVent BioPharma had 8 more articles in the media than Grifols. MarketBeat recorded 12 mentions for ArriVent BioPharma and 4 mentions for Grifols. Grifols' average media sentiment score of 1.22 beat ArriVent BioPharma's score of 0.24 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AVBP or TVTX?

In the previous week, Travere Therapeutics had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 16 mentions for Travere Therapeutics and 12 mentions for ArriVent BioPharma. Travere Therapeutics' average media sentiment score of 1.09 beat ArriVent BioPharma's score of 0.24 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or AVBP?

In the previous week, ArriVent BioPharma had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat ArriVent BioPharma's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, DYN or AVBP?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is DYN or AVBP more profitable?

ArriVent BioPharma's return on equity of -52.47% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% ArriVent BioPharma N/A -52.47% -48.68%

Does the media favor DYN or AVBP?

In the previous week, ArriVent BioPharma had 9 more articles in the media than Dyne Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat ArriVent BioPharma's score of 0.24 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

ArriVent BioPharma (AVBP) Competitors

$29.68 -0.32 (-1.07%)

As of 10:44 AM Eastern

Compare

AVBP vs. SRRK, GRFS, TVTX, CRSP, and DYN

Should you buy ArriVent BioPharma stock or one of its competitors? ArriVent BioPharma's main competitors and comparable companies include Scholar Rock (SRRK), Grifols (GRFS), Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ArriVent BioPharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Scholar Rock had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for Scholar Rock and 12 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.24 beat Scholar Rock's score of -0.01 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ArriVent BioPharma's return on equity of -52.47% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-159.92%	-90.71%
ArriVent BioPharma	N/A	-52.47%	-48.68%

Scholar Rock presently has a consensus target price of $57.71, suggesting a potential upside of 11.07%. ArriVent BioPharma has a consensus target price of $44.43, suggesting a potential upside of 49.69%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

Scholar Rock and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Grifols?

Grifols (NASDAQ:GRFS) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Grifols has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.42B	0.72	$454.82M	$0.19	41.43
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ArriVent BioPharma had 8 more articles in the media than Grifols. MarketBeat recorded 12 mentions for ArriVent BioPharma and 4 mentions for Grifols. Grifols' average media sentiment score of 1.22 beat ArriVent BioPharma's score of 0.24 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Grifols presently has a consensus price target of $10.00, suggesting a potential upside of 27.03%. ArriVent BioPharma has a consensus price target of $44.43, suggesting a potential upside of 49.69%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Grifols has a net margin of 5.54% compared to ArriVent BioPharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
ArriVent BioPharma	N/A	-52.47%	-48.68%

Grifols has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Summary

Grifols beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Travere Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Travere Therapeutics had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 16 mentions for Travere Therapeutics and 12 mentions for ArriVent BioPharma. Travere Therapeutics' average media sentiment score of 1.09 beat ArriVent BioPharma's score of 0.24 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. ArriVent BioPharma's return on equity of -52.47% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-52.47%	-48.68%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

ArriVent BioPharma presently has a consensus price target of $44.43, indicating a potential upside of 49.69%. Travere Therapeutics has a consensus price target of $61.67, indicating a potential upside of 1.08%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe ArriVent BioPharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Travere Therapeutics has higher revenue and earnings than ArriVent BioPharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Travere Therapeutics	$490.73M	11.72	-$25.55M	-$0.46	N/A

ArriVent BioPharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

ArriVent BioPharma beats Travere Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
ArriVent BioPharma	N/A	-52.47%	-48.68%

ArriVent BioPharma has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,459.83	-$581.60M	-$4.76	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

In the previous week, ArriVent BioPharma had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat ArriVent BioPharma's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CRISPR Therapeutics presently has a consensus target price of $68.06, indicating a potential upside of 28.42%. ArriVent BioPharma has a consensus target price of $44.43, indicating a potential upside of 49.69%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

CRISPR Therapeutics and ArriVent BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, ArriVent BioPharma had 9 more articles in the media than Dyne Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat ArriVent BioPharma's score of 0.24 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Dyne Therapeutics presently has a consensus target price of $34.42, suggesting a potential upside of 34.40%. ArriVent BioPharma has a consensus target price of $44.43, suggesting a potential upside of 49.69%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ArriVent BioPharma's return on equity of -52.47% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
ArriVent BioPharma	N/A	-52.47%	-48.68%

Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dyne Therapeutics beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.38B	$3.69B	$6.96B	$13.10B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-8.20	10.23	269.57	25.32
Price / Sales	N/A	1,285.96	595.01	100.00
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	3.99	17.54	13.06	6.29
Net Income	-$166.31M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-3.76%	0.19%	0.47%	0.89%
1 Month Performance	-8.79%	-0.03%	1.11%	0.85%
1 Year Performance	59.40%	53.11%	66.38%	20.25%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.3664 of 5 stars	$29.68 -1.1%	$44.43 +49.7%	+66.5%	$1.38B	N/A	N/A	40	News Coverage Positive News Earnings Report Analyst Forecast
SRRK Scholar Rock	1.6926 of 5 stars	$47.79 +4.2%	$56.21 +17.6%	+65.9%	$5.49B	N/A	N/A	140	Analyst Forecast Analyst Revision
GRFS Grifols	4.9028 of 5 stars	$8.08 +2.8%	$10.00 +23.7%	-25.5%	$5.35B	$8.51B	42.54	25,247	Positive News Short Interest Decrease
TVTX Travere Therapeutics	1.7733 of 5 stars	$56.02 +1.9%	$52.58 -6.1%	+240.3%	$5.11B	$490.73M	N/A	460	Analyst Revision
CRSP CRISPR Therapeutics	3.6203 of 5 stars	$53.07 +7.1%	$68.11 +28.3%	-6.7%	$4.78B	$3.51M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, TVTX, CRSP, and DYN

How does ArriVent BioPharma compare to Scholar Rock?

Summary

How does ArriVent BioPharma compare to Grifols?

Summary

How does ArriVent BioPharma compare to Travere Therapeutics?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, TVTX, CRSP, and DYN

How does ArriVent BioPharma compare to Scholar Rock?

Does the media refer more to SRRK or AVBP?

Do institutionals and insiders hold more shares of SRRK or AVBP?

Is SRRK or AVBP more profitable?

Do analysts rate SRRK or AVBP?

Which has more risk & volatility, SRRK or AVBP?

Which has stronger valuation & earnings, SRRK or AVBP?

Summary

How does ArriVent BioPharma compare to Grifols?

Which has stronger earnings & valuation, GRFS or AVBP?

Do institutionals and insiders hold more shares of GRFS or AVBP?

Does the media refer more to GRFS or AVBP?

Do analysts recommend GRFS or AVBP?

Is GRFS or AVBP more profitable?

Which has more volatility & risk, GRFS or AVBP?

Summary

How does ArriVent BioPharma compare to Travere Therapeutics?

Does the media prefer AVBP or TVTX?

Is AVBP or TVTX more profitable?

Do analysts recommend AVBP or TVTX?

Do insiders & institutionals believe in AVBP or TVTX?

Which has better earnings & valuation, AVBP or TVTX?

Which has more volatility and risk, AVBP or TVTX?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Is CRSP or AVBP more profitable?

Which has higher earnings and valuation, CRSP or AVBP?

Do insiders & institutionals have more ownership in CRSP or AVBP?

Which has more volatility & risk, CRSP or AVBP?

Does the media favor CRSP or AVBP?

Do analysts rate CRSP or AVBP?

Summary

How does ArriVent BioPharma compare to Dyne Therapeutics?

Does the media favor DYN or AVBP?

Do analysts rate DYN or AVBP?

Is DYN or AVBP more profitable?

Which has more volatility and risk, DYN or AVBP?

Which has stronger earnings & valuation, DYN or AVBP?

Do institutionals & insiders have more ownership in DYN or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools